menu
    • menu
    [{"orgOrder":0,"company":"CinPhloro Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinPhloro Pharma, a CinRx Portfolio Company, Dosed First Participant in Phase 2 Enviva Study of CIN-103 for Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Phloroglucinol","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinPhloro Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CinPhloro Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinPhloro Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by CinPhloro Pharma

    Menu

    CinPhloro Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CinPhloro Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            CinPhloro Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Phloroglucinol

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CinPhloro Pharma, a CinRx Portfolio Company, Dosed First Participant in Phase 2 Enviva Study of CIN-103 for Ir...

                            Details : CIN-103 (phloroglucinol) is a voltage-gated calcium channel blocker. It is being evaluated as a new approach for the chronic treatment of irritable bowel syndrome with predominant diarrhea (IBS-D).

                            Brand Name : CIN-103

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 22, 2024

                            Lead Product(s) : Phloroglucinol

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth